Company Overview

CytoDyn is a publicly traded biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses. CytoDyn's lead product candidate, leronlimab (PRO 140), has the potential to drive groundbreaking advancements in developing the next generation of HIV treatments.

CytoDyn CEO Highlights leronlimab (PRO 140) for Investors

Interview focused on company milestones, a pending acquisition and an array of new indications beyond the expected FDA approval for HIV treatment

View Video
CytoDyn CEO Highlights leronlimab (PRO 140) for Investors
View Detailed Stock Data

Stock Info

CYDY Symbol
OTCQB Market
Market Cap

Upcoming Events

Recent Events

2019 Conference on Retroviruses and Opportunistic Infections (CROI)

March 4 - March 7, 2019

CytoDyn’s Poster at CROI 2019:
Poster # 486: PRO 140 (leronlimab) SC: Long-Acting, Single-Agent Maintenance Therapy for HIV-1 Infection

  • Presenters: Drs. Kush Dhody and Nader Pourhassan
  • Date: Thursday, March 7, 2:30pm-4:00pm, Poster Hall – 4EF

View Press Releases

Recent News